Sorafenib-induced eruptive melanocytic lesions

Arch Dermatol. 2008 Jun;144(6):820-2. doi: 10.1001/archderm.144.6.820.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Benzenesulfonates / administration & dosage
  • Benzenesulfonates / adverse effects*
  • Biopsy
  • Carcinoma, Renal Cell / drug therapy
  • Carcinoma, Renal Cell / secondary
  • Diagnosis, Differential
  • Drug Eruptions / etiology*
  • Drug Eruptions / pathology
  • Female
  • Follow-Up Studies
  • Humans
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology
  • Male
  • Middle Aged
  • Nevus, Pigmented / chemically induced*
  • Nevus, Pigmented / pathology
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / administration & dosage
  • Pyridines / adverse effects*
  • Receptors, Vascular Endothelial Growth Factor
  • Skin / pathology
  • Skin Neoplasms / chemically induced*
  • Skin Neoplasms / pathology
  • Sorafenib

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib
  • Receptors, Vascular Endothelial Growth Factor